ETV6 and acute lymphoblastic leukemia: In this paper we evaluated the efficacy of SYK inhibition only in ETV6-RUNX1 ALL since this subgroup’s results are particularly interesting due to its usually good prognosis, but with patients experiencing relapse many years later after stopping therapy, however, this does not exclude that other pediatric-relapsed ALL subtypes could benefit from the use of SYK inhibitors.